Nivolumab/Ipilimumab Continues to Show Survival Benefit in Melanoma
The CheckMate 067 trial found that, at a 10-year follow-up, nivolumab/ipilimumab elicited a median OS of 71.9 months in patients with previously untreated, advanced melanoma.
Related Articles
Addressing Unmet Needs in Synovial Sarcoma and Recent FDA Approval of Afami-cel
Panelists discuss how the major unmet needs in treating synovial sarcoma include developing targeted therapies that effectively address the SS18::SSX fusion oncogene, improving early detection…
Novel HER2 TKI Shows Preliminary Activity in Breast Cancer Brain Metastases
Phase 1 data may support further development of ZN-1041 combination therapies for a larger breast cancer population.
Clinical Practice Insights Reveal the Complexity of Lymphoma Subtypes and Advances in First-Line Treatments: With Chandler Park, MD; and Joshua Brody, MD
Chandler Park, MD and Joshua Brody, MD discusses treatment challenges posed by the diverse spectrum of lymphomas, ranging from indolent subtypes, to aggressive diseases like…
CDC awards $2.3M research grant for young patients with breast cancer
The CDC has awarded Weill Cornell Medicine a 5-year, $2.3 million grant to advance equitable access to care for young patients with breast cancer. The…
Market trouble threatens Labour’s economic plans
Chancellor Rachel Reeves may have to choose between tax rises and spending cuts, writes Henry Zeffman.
New Ancestry-adjusted Lung Cancer Prediction Model
A new ancestry-adjusted risk prediction model, Genomic-informed Care for Motivating High Risk Individuals Eligible for Evidence-based Prevention (GREAT), may aid patients in decision-making around lung…
Tricking cells into trashing cancer
In a study published today in the Journal of Clinical Investigation, Fred Hutch Cancer Center cancer chemical biologist Behnam Nabet and his collaborators describe how…
A phase I study of convection-enhanced delivery (CED) of liposomal-irinotecan using real-time magnetic resonance imaging in patients with recurrent high-grade glioma
Journal of Neuro-Oncology – Irinotecan demonstrates anti-tumor efficacy in preclinical glioma models but clinical results are modest due to drug delivery limitations. Convection enhanced delivery…
Lombardi Comprehensive Cancer Center | Washington D.C. DC
Lombardi Comprehensive Cancer Center, Washington D. C. 3,084 likes · 22 talking about this · 4,338 were here. Georgetown Lombardi defeats cancer through scientific discovery…
Victoria’s Secret Global Fund for Women’s Cancers Career Development Awards, in Partnership with Pelotonia & AACR
$206,000 over two years for female assistant professors conducting research with a direct applicability and relevance to the understanding, prevention, interception, early detection, diagnosis, or…
